Below are the most recent publications written about "Tumor Microenvironment" by people in Profiles.
-
Kane GI, Diaz-Infante MB, Wigglesworth K, Lusi E, Brassil M, Rozen EJ, Kady J, Mori H, Lukas J, Naylor T, Dinnell RW, Murphy KC, Alarcon CBB, Ruscetti M, Brehm M, Shohet JM, Atukorale PU. Tumor Homing Nanoparticle Immunotherapy for Acute Clearance and Mitigation of T-cell Exhaustion in Humanized High-Risk Neuroblastoma. Mol Cancer Ther. 2026 Jul 02; 25(7):1144-1156.
-
Specht E, Pakanati L, Wu MJ, Jenkins RW, Effiom DN, Bardeesy N, Bernstein BE, Sade-Feldman M, Lian CG, Boland GM, Torlai Triglia E, Cohen S. Loss of tumor-infiltrating lymphocytes and poor response to immunotherapy in IDH GOF mutant melanoma. JCI Insight. 2026 Jun 08; 11(11).
-
Fernando W, Clucas J, Rizzo A, Singer R, Goode E, Tiu C, Layzell S, Konecnik J, Wilson R, Wicky John S, Jouny S, Guppy N, Boulat V, Mannion J, Goicoechea M, Tan S, Lawson S, Starling C, Elshtein G, Ravindran N, Montgomery AB, Andres-Ejarque R, Allen M, Lumbard S, Wallberg F, Betteridge K, Scrimgeour R, Robertson D, Ward G, Sims M, Smyth T, Samson AL, Murphy JM, Kolarevic Ivankovic D, Arwert EN, Calado DP, Grigoriadis A, Smalley MJ, Melcher A, Haider S, Lawrence T, Roxanis I, Tutt ANJ, Tenev T, Meier P. Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy. Nat Commun. 2026 Mar 06; 17(1).
-
Tang X, Liu L, Gao M, Duan P, Li S, Yuan Z, Xia Q, Xi L, Tan Y. Single-cell transcriptomics identifies fibroblast associated immune heterogeneity and prognostic signatures in bladder cancer. Sci Rep. 2026 Feb 03; 16(1):7151.
-
Zhan X, Xiao H, Wang Q, Luo J, Ma L, Zhang X, Tang J, Meng X. Natural killer cell nano-engagers drive ferroptosis-immunomodulation synergy via inhibition of the Interleukin-6-JAK2-STAT3 Axis. J Control Release. 2026 02 10; 390:114581.
-
Kumar S, Richter J, Usmani SZ, Cohen YC, Ye JC, Mateos MV, Hungria V, Zamagni E. Extramedullary Disease-Achilles Heel in Myeloma? Am J Hematol. 2026 03; 101(3):521-536.
-
Sun JX, Ma SY, Xu JY, Abudureyimu M, An Y, Xu JZ, Zhang SH, Zhang ZY, Guo CX, Liu BL, Wang SG, Xia QD. Escherichia coli Nissle 1917 outer membrane vesicles encapsulating oncolytic virus remodel tumor-associated macrophages and kill prostate cancer cells. J Control Release. 2026 02 10; 390:114514.
-
Giovannoni F, Strathdee CA, Faust Akl C, Andersen BM, Li Z, Lee HG, Torti MF, Rone JM, Duart-Abadia P, Molgora M, Kong L, Floyd M, Teng J, Gyulakian Y, Grzesik P, Farkaly T, Denslow A, Feau S, Rodriguez-Sanchez I, Jacques J, Colonna M, Kennedy EM, Cheema T, Lerner L, Qu?va C, Quintana FJ. Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy. Nat Cancer. 2025 Dec; 6(12):1994-2010.
-
Murphy KC, DeMarco KD, Zhou L, Peura J, Giwa HK, Lopez-Diaz Y, Ho YJ, Li J, Bai S, Simin K, Zhu LJ, Pitarresi JR, Mercurio AM, Ruscetti M. MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer. Cancer Res. 2025 Nov 14; 85(22):4359-4379.
-
Sarkar S, Chang CI, Jean J, Wu MJ. TCA cycle-derived oncometabolites in cancer and the immune microenvironment. J Biomed Sci. 2025 Sep 10; 32(1):87.